A5086137912- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Retinoids in leukemia and cellular processes
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Histone Deacetylase Inhibitors Research
- Lung Cancer Treatments and Mutations
- Viral-associated cancers and disorders
- Cancer Treatment and Pharmacology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Epigenetics and DNA Methylation
- Mycobacterium research and diagnosis
- Adolescent and Pediatric Healthcare
- Antimicrobial Resistance in Staphylococcus
- CNS Lymphoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Methemoglobinemia and Tumor Lysis Syndrome
- Safe Handling of Antineoplastic Drugs
Michigan Medicine
2016-2025
University of Michigan
2015-2025
Michigan United
2019
Ann Arbor Center for Independent Living
2017
University Health System
2014
The University of Texas MD Anderson Cancer Center
2012-2013
Harper University Hospital
2010-2011
Eugene Applebaum College of Pharmacy and Health Sciences
2010
Wayne State University
2010
Acute erythroid leukemia treatment is associated with poor survival. The most common treatments are intensive chemotherapy regimens and hypomethylating agents. Choice of preferred therapy complex, data conflicting on the optimal regimen. definition AEL has also shifted time but impacts these changes survival reporting largely unknown.We designed a single-center, retrospective review patients meeting 2001 World Health Organization acute leukemia. Patients were treated an or agent primary...
Asparaginase (ASNase)-based chemotherapy regimens significantly improve survival outcomes in children, adolescent and young adult (AYA), even adults with acute lymphoblastic leukemia/lymphoma (ALL); however, the incidence severity of ASNase-associated adverse events (AEs) may differ from those reported children. Strategies to mitigate, monitor for, manage toxicities that allow ALL patients receive full ASNase courses are needed. A representative 12-member panel experts who treat AYA...
Posaconazole is the prophylactic antifungal of choice for patients with haematological malignancies at high risk invasive fungal infections (IFIs). Studies have demonstrated that subtherapeutic concentrations posaconazole are associated breakthrough and specific factors troughs suspension formulation been identified. However, these not evaluated in a large patient population recently approved tablet formulation.To determine receiving as IFI prophylaxis.From 1 February 2013 to 31 March 2015...
The incidence of Clostridium difficile infection (CDI) in adults with malignancy is 7%-14% compared 1%-2% the general hospitalized population. Despite increased CDI this population, a major concern propensity to recur, leading delays therapy impacting outcomes. We conducted retrospective case-control study identify risk factors for recurrent (rCDI) and determine impact rCDI on adult patients haematological malignancy.Adult haematology from June 2010 December 2014 were divided into two...
The association of posaconazole serum concentrations and toxicity is unclear. An assessment whether levels obtained with the delayed-release tablet (DRT) formulation are correlated abnormal liver function test (LFT) results and/or QTc prolongation was undertaken.This a multicentre, retrospective, observational study adult patients cancer between 26 November 2013 14 2014. Patients were included if they received DRT level days 5 14. Clinical data, including demographics, hepatotoxic...
The availability of Erwinia Asparaginase has been limited across the world due to manufacturing shortages or for some countries high acquisition cost, putting patients at risk inferior outcomes. This manuscript provides guidance on how manage hypersensitivity reactions and utilize therapeutic drug monitoring (TDM) conserve limit use. clinical financial impact a multidisciplinary committee are also discussed. Faced with global shortage, asparaginase allergy was created review all therapy,...
Daptomycin is typically the treatment of choice for vancomycin resistant Enterococcus (VRE) bloodstream infections (BSI) in patients with hematological malignancies, but increasingly daptomycin nonsusceptible VRE are being reported. We reviewed our experience BSI among malignancies. compared risk factors and outcomes 20 (case patients) 40 matched control susceptible BSI. Case had more complications (6/20 vs. 2/40, p = .013); all-cause mortality was similar both groups. By multivariable...
There is minimal data evaluating the safety of antibiotic de-escalation in patients with acute myeloid leukemia (AML) fever and ongoing neutropenia. Therefore, this study evaluated prescribing, infection-related outcomes, patient outcomes an initiative.This pre-post quasiexperimental included adult AML hospitalized febrile An guideline was implemented January 2017, which promoted or discontinuation intravenous antipseudomonal β-lactams. The primary outcome assessment incidence bacterial...
Asparaginase is commonly de-emphasized/omitted in adult acute lymphoblastic leukemia regimens due to poor tolerability, including hepatotoxicity (HTX). Adult patients (n = 100) given induction therapy containing pegylated asparaginase (PEG) from January 2008 February 2016 were evaluated for HTX. Sixteen met criteria HTX (direct bilirubin >3 g/dL). A multivariable model identified body surface area >2m2 (OR 7.40; 95% CI: 1.73–31.61, p .007), albumin <3 mg/dL 4.62; 1.09–19.68, .038), and...
Daratumumab and elotuzumab have demonstrated improvements in overall response rates (ORR) progression-free survival (PFS) relapsed/refractory multiple myeloma (RRMM). There is a lack of comparative clinical trials an even larger consensus on the optimal integration these novel agents into treatment paradigm. Clinical outcomes were compared retrospectively 37 patients who received daratumumab before (dara-first, n = 23) (elo-first, 14). ORR to first monoclonal antibody was not different...
Purpose There is a lack of high-level evidence identifying meaningful outcomes and the optimal place in therapy rasburicase patients with, or at high risk for tumor lysis syndrome. The primary objective this study was to evaluate characterize resulting from an institution-specific guideline emphasizing supportive care, xanthine oxidase inhibitors, lower doses rasburicase. Methods In retrospective chart review, we compared conservative dosing, accordance with newly developed UMHS syndrome...
Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison safety/efficacy CPX-351 against regimens containing purine analogue high-dose (HIDAC). This retrospective compared complete response rates with/without count recovery (CR/CRi) between HIDAC-based in 169 patients with newly diagnosed sAML. The CR/CRi rate was 62.7% the therapy arm...